Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...
Auteurs principaux: | Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Elsevier
2019
|
Documents similaires
-
International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
par: Williamson, K, et autres
Publié: (2018) -
Vedolizumab for the treatment of chronic pouchitis
par: Travis, S, et autres
Publié: (2023) -
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
par: Renske W. M. Pauwels, et autres
Publié: (2020-12-01) -
Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
par: Suzanne I. Anjie, et autres
Publié: (2024-02-01) -
Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
par: Matthew Luzentales-Simpson, et autres
Publié: (2021-02-01)